Published in J Am Soc Nephrol on April 01, 1999
Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther (2006) 1.15
Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy (2009) 0.89
Clinical features and renal outcome in lupus patients with diffuse crescentic glomerulonephritis. Rheumatol Int (2009) 0.88
The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol (2010) 0.87
Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother (2009) 0.84
Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol (2007) 0.84
An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol (2009) 0.82
Fatal acute pancreatitis complicated by pancreatic pseudocysts in a patient with systemic lupus erythematosus. Rheumatol Int (2009) 0.81
Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol (2010) 0.81
Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int (2006) 0.80
Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice. Clin Exp Immunol (2001) 0.77
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus]. Z Rheumatol (2007) 0.76
A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience. Lupus Sci Med (2016) 0.75
Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model. Int J Mol Sci (2015) 0.75
Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Eurasian J Med (2009) 0.75
Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Hum Gene Ther Methods (2012) 0.75
Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease. J Am Heart Assoc (2017) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Small-vessel vasculitis. N Engl J Med (1997) 7.20
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 3.57
International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Am J Clin Pathol (1999) 3.31
Rituximab treatment of idiopathic membranous nephropathy. Kidney Int (2007) 2.85
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker. Kidney Int (2007) 2.84
Identifying specific causes of kidney allograft loss. Am J Transplant (2008) 2.77
Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med (1992) 2.66
Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol (1989) 2.40
The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant (2010) 2.40
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant (2013) 2.35
Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int (1992) 2.30
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol (1991) 2.14
Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol (1996) 2.08
Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int (2006) 2.06
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol (1996) 1.95
Antineutrophil cytoplasmic autoantibodies and associated diseases: a review. Am J Kidney Dis (1990) 1.95
Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int (1994) 1.91
The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol (1995) 1.91
A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis (1995) 1.85
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
The living donor in kidney transplantation. Ann Intern Med (1987) 1.81
Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest (1966) 1.81
Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA (1976) 1.77
Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int (2007) 1.77
Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant (2009) 1.71
Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood (1990) 1.71
Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant (2006) 1.70
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int (2000) 1.64
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. Kidney Int (2000) 1.53
Efficacy of treatment for unexplained infertility. Fertil Steril (1998) 1.48
Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis (1996) 1.47
Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest (1984) 1.46
Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant (2006) 1.42
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol (1997) 1.40
Therapy of membranous nephropathy: what to do after the after (meta) analyses. J Am Soc Nephrol (1995) 1.39
Renoprotective therapy: how good can it get? Kidney Int (2000) 1.39
Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int (1998) 1.37
Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol (2001) 1.36
Interleukin-8 delays spontaneous and tumor necrosis factor-alpha-mediated apoptosis of human neutrophils. Kidney Int (1998) 1.34
Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Am J Pathol (1996) 1.33
Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol (1987) 1.33
Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int (1992) 1.32
Monoclonal antibodies to human renal basement membranes: heterogenic and ontogenic changes. Kidney Int (1983) 1.31
Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant (1998) 1.28
Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin Immunol Immunopathol (1989) 1.28
CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 1.27
Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med (1985) 1.26
Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. Am J Pathol (2001) 1.26
Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant (2007) 1.25
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant (2004) 1.23
Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int (2006) 1.23
Infections associated with subclavian Uldall catheters. Arch Intern Med (1983) 1.21
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant (2007) 1.19
Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. J Leukoc Biol (1992) 1.19
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int (2007) 1.18
Microalbuminuria, peripheral artery disease, and cognitive function. Kidney Int (2007) 1.18
Renal artery dissection causing renal infarction in otherwise healthy men. Am J Kidney Dis (1997) 1.17
Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol (2000) 1.13
Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol (1983) 1.13
Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant (2013) 1.12
Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant (2006) 1.12
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis (1990) 1.11
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis (2000) 1.08
Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant (2008) 1.07
The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int (1987) 1.07
Epidermolysis bullosa acquisita antigen, a major cutaneous basement membrane component, is synthesized by human dermal fibroblasts and other cutaneous tissues. J Invest Dermatol (1986) 1.05
Some hemodynamic determinants of immune complex trapping by the kidney. Kidney Int (1978) 1.05
Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol (1987) 1.04
Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol (2000) 1.04
Diagnostic predictive value of ANCA serology. Kidney Int (1998) 1.04
Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis (1998) 1.03
Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res (2009) 1.03
Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol (1994) 1.03
Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis (2000) 1.02
Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense. Infect Immun (1986) 1.02
The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis (1991) 1.02